KarXT demonstrated statistically significant and clinically meaningful improvements in positive and negative symptoms of schizophrenia compared to placebo, as measured by primary and secondary endpoints
8 Likes
This is great, The Lancet has enormous prestige. Roluperidone and KarXT are our next hopes, both coming to the market next year. We must pay attention to February 26 (for roluperidone) and July-September (for KarXT)
What needs to be seen regarding the treatment of negative symptoms is the SANS scale (Scale for the Assessment of Negative Symptoms) by KarXT. They haven’t published it yet I think.
4 Likes